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Neutrophils and eosinophils are granulocytes which are characterized by the presence of granules in the
cytoplasm. Granules provide a safe storage site for granule proteins that play important roles in the
immune function of granulocytes. Upon granulocytes activation, diverse proteins are released from the
granules into the extracellular space and contribute to the fight against infections. In this article, we
describe granule proteins of both neutrophils and eosinophils able to kill pathogens and review their
anticipated mechanism of antimicrobial toxicity. It should be noted that an excess of granules protein
release can lead to tissue damage of the host resulting in chronic inflammation and organ dysfunction.
Copyright © 2020, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).University of Bern, Inselspital,
ety of Allergology.
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Granulocytes are polymorphonuclear (PMN) leukocytes that
comprise neutrophils, eosinophils, and basophils, of which neu-
trophils are the most frequent type found in blood. These white
blood cells are an essential part of the innate immune system andvier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
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pathological conditions, might also cause tissue injury.1,2 Granules
are formed during the differentiation and described as the hallmark
of granulocytes that storage “pre-packed” proteins which can be
released into the extracellular space upon stimulation. These
diverse mediators, once released to the extracellular space, are able
to encounter and destroy all types of microorganism, and, in the
case of eosinophils and basophils, also known to orchestrate hy-
persensitivity reactions.3 Granule proteins form together with a
fibrous scaffold build of mitochondrial DNA (mtDNA) extracellular
structures called extracellular traps (ETs) that can be formed by all
three granulocyte types. ETs comprise an efficient mechanism of
host defense through facilitating the binding and killing of invading
bacteria and fungi in the extracellular space. Granule proteins with
a high affinity for DNA are delivered into ETs and cause a high local
concentration of antimicrobial proteins and simultaneously reduce
the spread of harmful proteins such as proteinases to adjacent
tissues.4e10
The formation of granules (granulopoiesis) in neutrophils occurs
sequentially during myeloid cell differentiation and is regulated by
several myeloid transcription factors that are active at specific
stages of neutrophil development. Four morphologically distinct
granule populations can be distinguished: azurophilic (primary),
specific (secondary), gelatinase (tertiary) and secretory gran-
ules.11,12 Azurophilic granules are formed during the promyelocytic
stage and represent the largest granules in neutrophils. They
contain the most toxic mediators including elastase, myeloperox-
idase (MPO), cathepsins as well as defensins, and contribute mainly
to the antimicrobial effects of neutrophils.13e16 In the meta-
myelocyte stage, specific granules emerge that are characterized by
a high content of the glycoprotein lactoferrin. In addition, they also
contain antimicrobial compounds, including neutrophil gelatinase-
associated lipocalin (NGAL), human cathelicidin (hCAP-18) and
lysozyme.16 The smallest granules, the gelatinase granules, are the
last population formed during neutrophil maturation. They contain
metalloproteases, including gelatinase and leukolysin, as well as of
few antimicrobials.16 These three classical granules are formed by
budding from the Golgi.16 In contrast, the secretory vesicles are
formed through endocytosis at the end of neutrophil maturation,
accordingly, they incorporate mainly plasma-derived proteins such
as albumin.16
Eosinophil granules are subdivided in primary and secondary
granules. Primary granules contain Charcot-Leyden crystal protein
and eosinophil peroxidase (EPO). Secondary granules are composedFig. 1. Overview of granule proteins in eosinophils and neutrophils. The figure illustrates the
granules are divided in primary granules and secondary granules. The secondary granules ar
are developed during different stages of neutrophil development. The three subsets are deof matrix with a crystalline core. Eosinophil cationic protein (ECP),
eosinophil-derived neurotoxin (EDN) and EPO are found in the
matrix, meanwhile major basic protein (MBP) is restrained in the
crystalline core.17
Antimicrobial proteins (AMP) are ancient molecules also pre-
sent in granules of both neutrophils and eosinophils evolved as
part of host defense to eliminate pathogenic bacteria, fungi, par-
asites and viruses.18 Their main modes of action consist of dis-
ruptions of bacterial membrane. Furthermore AMPs are able to
vanish the electrochemical gradient of the membrane by pore
formation or to interfere with DNA, protein or cell wall synthesis
and inhibit protein folding after entering into the cytoplasm.19
AMPs share some structural features: 1) smaller length than 60
amino acids, 2) often a net positive charge, 3) broad-spectrum
antimicrobial activity at physiological conditions and 4) hydro-
phobic and hydrophilic amino acids clusters adopted in an
amphipathic shape.20
Granules of both neutrophils and eosinophils contain proteases
which are important for physiological processes. However, their
excessive, prolonged or inappropriate proteolytic activity is
involved in the offset of diseases.21 Proteases are subdivided in four
classes based on their biochemistry of the active site: 1) serine
proteases, 2) metalloproteases, 3) thiol-proteases and 4) aspartate
proteases. Serine proteases and metalloproteases are most active at
neutral pH thus are involved in extracellular protein digestion.21 On
the other hand, thiol-proteases and aspartate proteases are most
active at acidic pH and participate in the degradation of intracel-
lular proteins.21 Peroxidases in granulocytes are members of the
heme peroxidase superfamily.22 Oxidants and reactive oxygen
species (ROS) are required for many physiological processes,
nonetheless their excessive production is involved in pathophysi-
ological processes. Peroxidases are able to interact with H2O2 and
are required for its cytotoxicity.23
In this article, we summarize our current understanding on the
mechanisms of toxicity of neutrophil and eosinophil granule pro-




Charcot-Leyden crystal (CLC) protein, also known as galectin 10,
belongs to the galectin superfamily24 and is only found in humans,different granule subsets of human eosinophil and neutrophil granulocytes. Eosinophil
e composed of two compartments: a matrix and a crystalline core. Neutrophil granules
fined by their morphology, their time of biosynthesis and their protein content.
Table 1
Antimicrobial mechanisms mediated by granule proteins of eosinophils and
neutrophils.
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but not inmouse eosinophils.25 Unlike other galectin members, CLC
does not have the ability to bind b-galactosidase24 or any known
mammalian glycan structures.26 CLC is found to interact with gly-
cosylated EDN and ECP, two human eosinophil granule cationic
RNases, but induces no inhibitory function upon binding. Upon IFN-
g activation of eosinophils, CLC associates rapidly with CD63 pos-
itive secondary granules and EDN, suggesting a role of CLC in ve-
sicular transport of cationic RNases.26 The presence of CLC is
required for eosinophil granulogenesis during differentiation.26
Furthermore, CLC has been shown to be involved in inflammation
in allergic, parasitic and other eosinophil-associated diseases and
inflammatory reactions.27
Eosinophil peroxidase (EPO, also known as EPX) catalyzes the
two-electron redox reaction H2O2 þ X þ Hþ / HOX þ H2O
similar to other peroxidases.28 Unlike for MPO, the physiologic
substrate for EPO is still mainly uncertain. Three rather unusual
substrates including Br, NO2 and the pseudohalide thiocyanate
(SCN) are involved in the oxidation by EPO and H2O2.28 During
degranulation, EPO can be released into large cytoplasmic vacu-
oles (phagosome) or directly onto the surface of a target.29 Per-
oxidaseeH2O2eiodide reaction leads to the iodination of protein
and killing of bacteria.30 EPO interacts with the superoxide
generated by the NADPH oxidase to provide the bactericidal ac-
tivity of eosinophils.31 EPO exhibits cytotoxicity through the
release of peroxidase-derived oxidants towards mammalian tu-
mor cells,32 HIV-133 and schistosomula of Schistosoma mansoni34
when the peroxidase is combined with H2O2 and a halide. Eo-
sinophils adhere to schistosomula coated with antibody and
complement. Upon release EPO binds to the surface of schisto-
somula. The binding itself is non-toxic but the presence of surface-
bound EPO can enhance the eosinophil-mediated toxicity against
the parasite.35 Similar effect mediated by EPOeH2O2ehalide sys-
tem occurs towards host endothelial cells and is observed in
eosinophilic endocarditis.36 Mycobacterium tuberculosis treated
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fragmentation and cell lysis within 120 min, particularly in the
presence of H2O2.37 Binding of EPO to gram-negative bacteria
membranes and subsequent inhibition of LPS and lipid A occurs in
a haloperoxidase-independent manner.38
Secondary granule proteins
Eosinophil granule proteins EDN/RNase 2 and ECP/RNase 3 are
reported to be closely related proteins and part of RNase A super-
family.39 RNase A superfamily itself is an important part of the
human AMP family.40 Members of the RNase A superfamily share a
similar primary sequence and structural similarities such as 6e8
conserved cysteine residues forming characteristics distinct disul-
fide bonds and conserved histidines, as well as a lysine in the active
center to catalyze the ribonuclease activity.41,42 The ribonucleases
are reported inmucosal secretions, in several types of immune cells
as well as in major organs.42
EDN exhibits ribonuclease activity against single stranded RNA
viruses including respiratory syncytial virus,43 hepatitis B virus44
and HIV.45 On the other hand, ECP has antibacterial and antipara-
sitic properties.39,46e48 EDN has been shown to be less cationic and
less cytotoxic than ECP and was originally described as a neuro-
toxin.39 In contrast, ECP is uniquely expressed in eosinophils, more
cationic and exhibits significant less ribonuclease activity
compared to EDN or RNase A.49 In fact, the cytotoxic activity of ECP
is independent of its ribonuclease activity.49 EDN displays the
ability to penetrate the viral capsid thus gaining access to the viral
RNA genome and inactivating extracellular virions by its ribonu-
clease activity.50 Both EDN and ECP mediate cytotoxic effects on
keratinocytes through the production of ROS and induction of
apoptosis.51 Additionally, ECP has been shown to promote kerati-
nocyte cellematrix detachment and to upregulate MMP9 expres-
sion.51 ECP is released in associationwith mitochondrial DNA in the
context of forming eosinophil extracellular traps (EETs) which are
able to bind and to kill bacteria in the extracellular space.5,52,53
High-affinity binding of ECP to lipopolysaccharide (LPS) and
peptidoglycan causes destabilizing of the bacterial cell wall and
subsequently cell membrane depolarization.54 Moreover, ECP-LPS
interactions trigger LPS aggregation and neutralization of LPS-
stimulated TNF-a production.55 ECP binds to the membrane
phospholipid polar heads by electrostatic interactions. Following
clustering of the liposomeeprotein complexes, liposome aggrega-
tion and destabilization of the lipid bilayer occurs that lead ulti-
mately to membrane disruption and release of the liposome
content.56 ECP interacts preferably with anionic and zwitterionic
phospholipids of cell membranes. The anionic lipids are exposed on
the external side of microbial membranes but sequestered on
cytoplasmic side of eukaryote host cell membrane explaining a
potential mechanism of antibacterial properties.57 Under in vitro
condition, ECP was shown to form amyloid-like fibrils. The
amyloid-type aggregates of ECP led to cell agglutination and bac-
teria clearance preceding the cell death.58
Major basic protein 1 (MBP-1) is a cationic protein stored in the
crystalline core of the eosinophil secondary granule.59 MBP-1 is
produced as a pre-protein which lacks toxicity owing to the pres-
ence of the N-terminal domain. Interestingly, the C-terminal region
crystallizes to prevent intracellular toxicity when the pro-MBP-1 is
cleaved upon granule maturation. Activation of eosinophils de-
creases the pH within the granules leading to the breakdown of the
crystalline core and release of MBP-1 as an active cytotoxic pro-
tein.59 Damage induced by MBP-1 is not selective, hence is directed
against pathogen and mammalian target cells.46,59 MBP-1 exhibit
toxicity against bacteria,46,48,59 schistosomula of S. mansoni46 as
well as host tissue associated with eosinophil infiltration such asintestine, spleen, skin, mucosa and peripheral blood mononuclear
cells.59,60 MBP-1 and EPO are able to cause degranulation of human
eosinophils as potent as sIgA beads, a strong agonist for eosino-
phils.61 Furthermore, MBP-1 enhances production of the proin-
flammatory cytokine IL-8.61 MBP-1 is able to bind and to
permeabilize membranes similar to cytotoxicity mediated by ECP
that occurs through pore formation on bacterial cell mem-
branes.48,62 Furthermore, local perturbations of bacterial cell
membrane are observed following MBP-1 treatment.59 Moreover,
MBP-1 is able to form amyloids that facilitate antimicrobial activ-
ity,59 comparable to reports of ECP amyloid.58 Accelerating the fiber
formation by heparin decreases toxicity and is in line with the
observation of non-toxic large MBP-1 amyloid accumulation in
tissues.59 The extracellular deposits are proposed to function as
sequestration of toxic oligomers59 that can recruit inflammatory
cells,60 including macrophages for the process of phagocytosis.63
MBP and ECP were found attached to the DNA scaffold of EETs
in vitro,5 in colons of Crohn's disease patients,5 allergic asthma,64




MPO is a heme-containing peroxidase of the peroxidase super-
family. In combination with H2O2 and a halide, it catalyzes the
formation of reactive oxygen intermediates.66 MPO is released from
azurophilic granules of activated neutrophils either into the phag-
olysosome or directly into the extracellular space.21 Hypohalous
acids formed by MPO exhibit antibacterial, antiviral as well as
antifungal properties and are involved in chronic inflammation
when produced in excess.67 MPO is found in colocalization with
mtDNA within NETs.6
Serine proteases contain a catalytically essential serine residue
at their active side.21 They comprise the largest class of mammalian
proteases and are mainly synthesized as inactive precursors. The
exception are the three human leukocyte serine proteases elastase,
cathepsin G and proteinase 3 that are stored in an active form
within the azurophilic granules.68 Neutrophil serine proteases
exhibit antimicrobial activity against bacteria, yeast and fungi.21
Furthermore, they are involved in several non-infections inflam-
matory diseases, including arthritis,69 bullous pemphigoid,70,71
chronic inflammatory lung diseases72,73 and tissue damage
following ischemia/reperfusion injury.74 Cathepsin G-knockout
mice are more susceptible to Gram-positive bacteria whereas mice
lacking neutrophil elastase are more susceptible to Gram-negative
bacteria and enterobacteria species.75,76 Neutrophil elastase binds
the bacterial membrane and directly degrades the outer membrane
protein A of Escherichia coli or virulence factors of enterobacteria,
resulting in the loss of bacterial integrity and cell lysis.76,77 The
human neutrophil serine proteases are upregulated on the cell
surface upon activation. They mostly remain bound to the plasma
membrane during exocytosis of the granules allowing the neutro-
phils to modulate their inflammatory response through the pres-
ervation of their catalytic activity.78 Additionally, neutrophil serine
proteases display extracellular activities. Serine proteinases are
released in NET-forming neutrophils.4,79 After exocytosis, protein-
ase 3 is required for proteolytic processing of the human cath-
elicidin to its active form LL-37.80 Similarly, mature active IL-18 is
released of epithelial cells after stimulation with IFN-g in combi-
nation of proteinase 3 and LPS without the activity of caspase-1.81
In contrast, neutrophil elastase downregulates the biological ac-
tivity of IL-18 through proteolysis.82 Neutrophil elastase and
cathepsin G abolish the pro-inflammatory effect of bacterial
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cleaving caspase-8, cathepsin D is able to induce a proapoptotic
death pathway in neutrophils themselves.84,85 Moreover, neutro-
phil serine proteases are able to regulate chemokine activities by
proteolytic modifications. For example, the activity and stability of
CXCL8 and CXCL5 are enhanced following their N-terminal pro-
teolytic modification by proteinase 3 and cathepsin G.86,87 On the
other hand, cleavage of CCL3, CXCL12 and CXCR4 results in lower
chemotactic activity.88,89 Recently, it has been shown that fibroblast
activation protein e 1 alpha, a serine protease, is expressed in
neutrophils and involved in the activation of NADPH oxidase.90
In neutrophils, four small cationic peptides of a-defensins called
human neutrophil peptides 1, 2, 3 and 4 (HNP1-4) are secreted
upon activation and exhibit antibacterial, antiviral as well as anti-
fungal activity.91,92 Defensins are characterized by a b-sheet-rich
fold, a high cathodal electrophoretic mobility and a framework of
six disulphide-linked cysteines. Three subfamilies are identified: a-
and b-defensins that are formed by a triple-stranded b-sheet with a
“defensin” fold and q-defensins.93 HNP1 and HNP3 differ only at the
first residue, while HNP2 is proteolytic processed of one of these
two defensins.94 HNP1 and HNP3 have been characterized as NET-
associated proteins.79 Defensins are produced as prepropeptides.
First steps of maturation include removing of the signal peptide and
packaging of the inactive propeptides in azurophilic granules. The
full process occurs within the granules mediated by neutrophil
elastase and proteinase 3.95 HNPs are acting against Gram-positive
and Gram-negative bacteria through membrane permeabiliza-
tion.21 Defensins decrease the membrane potential of target cells
within minutes through the creation of small membrane channels
followed by the permeabilization of the cells after a short lag
period. Interestingly, cells can be rescued by removing the HNP-
containing media after 30 min, hence a second phase of injury
and continuing presence of HNP is necessary for cell lysis.91 HNP2
has been shown to form multimeric pores in lipid bilayers.96
Defensin-mediated bactericidal activity occurs by outer mem-
brane permeabilization following inner membrane permeabiliza-
tion.97 Synchronous inhibition of RNA, DNA and protein production,
as well as loss of cellular metabolites and altered ionic cellular
environment lead to loss of the bacterial colony-forming poten-
tial.97 Defensins interfere and also disrupt the virus fusion to the
host plasma membrane through inhibition of the interactions be-
tween viral glycoproteins and cellular receptors.92 In contrast to
antibacterial and antifungal mechanism, direct disruption of the
virus lipid bilayer does not occur. Viral envelopes are mainly
derived from host cell membranes helping the enveloped virus to
escape the defensins.92 Moreover, at sites of inflammations where
defensins are present at high concentrations, they can bind serine
proteinase inhibitors (serpins), particularly a1-proteinase inhibitor
(a1-PI) and a1-antichymotrypsin (a1-ACT), to prevent their activity
against serine proteases.98 Within the phagolysosome of neutro-
phils, increased proteolytic activity of serine proteases through
defensin-serpin binding may lead to enhanced phagocytic diges-
tion of microbes.98
Bactericidal/Permeability-Increasing Protein (BPI) belong to
the lipid transfer/LPS binding protein family that is characterized
by the binding of lipid substrates99 as well as to the tubular-lipid
binding protein (TULIP) family.100 BPI exerts bactericidal activity
against Gram-negative bacteria through the neutralization of LPS
by binding to the lipid A moiety.101 Penetration of the inner bac-
terial cell membrane induces membrane damage leading even-
tually to cell death.102 BPI-mediated toxicity occurs in two stages.
In an early, reversible sublethal phase, BPI acts on the outer bac-
terial membrane and induces growth arrest. Penetration of the
cell membrane leads to a time- and pH-dependent lethal stage
with the involvement of cytoplasmic membrane damage.102 BPI isable to reduce LPS-mediated neutrophil stimulation, pyrogenicity
and LPS-induced TNF-a production.103,104 BPI enhances the
interaction of bacterial outer membrane vesicles with dendritic
cells (DCs) and is involved in the LPS uptake and antigen pre-
sentation by DCs.105 In Gram-positive infections, binding of BPI to
bacterial lipopeptides and lipoproteins, as well as lipoteichoic acid
enhances their inflammatory effects.106 The LPS-binding protein
(LBP) moiety of the TULIP family binds to the same component of
LPS on gram-negative bacterial membrane as BPI. However, LBP
helps to initiate the host immune response by bringing small
amounts of LPS to effector cells.106,107
Secretory Leukoproteinase Inhibitor (SLPI), also known as anti-
leukoprotease (ALP), is a endogenous serine protease inhibitor
(serpin) produced by epithelial cells and some myeloid cells
including neutrophils.108 SLPI is mainly involved in the protection
of local tissues against inflammatory consequences that are caused
by proteases including cathepsin G, elastase and trypsin from
neutrophils.109 Furthermore, some studies propose antibacterial
and antifungal capacity for SLPI.110e112 While the proteinase
inhibitory activities are shown to be located at the COOH-terminal
domain, the antibacterial capacity against Gram-negative and
Gram-positive bacteria depend on the NH2-terminal domain.111
SLPI induces toxicity against E. coli by binding to DNA and mRNA
leading to inhibition of translation.110 Fungicidal activity of SLPI
emerge against metabolically active Aspergillus fumigatus and
Candida albicans. On the other hand, metabolically quiescent
A. fumigatus has been reported to be resistant against SLPI.112
Specific granule proteins
LL-37 is expressed by immune cells including neutrophils,
monocytes, mast cells, NK cells, B and T cells, as well as stem
cells.113 LL-37 is the mature peptide of 37 amino acids released from
the C-terminus of the propeptide hCAP18.114 hCAP18 is processed
by extracellular proteolysis of the C-terminal end of the human
cationic antimicrobial protein (hCAP).115 hCAP is the only cath-
elicidin family member, one of the major AMP families, known in
humans. They are comprised of a highly conserved N-terminal
signal peptide e “cathelin domain” e and a structurally variable
cationic AMP at the C-terminus.116 LL-37 is active against the
anionic membrane of Gram-positive and Gram-negative bacteria,
similar to other cationic AMPs. The positive charge of the peptide
enhances the binding to negatively charged bacterial membranes
rather than mammalian cell membranes.117 The importance of the
electrostatic attraction for the antibacterial capacity is underlined
by the fact that modification of the bacterial surface influences the
susceptibility of the cells to LL-37.118e120 LL-37 and its propeptide
hCAP18 are releasedwithin NETs. LL-37 binds to the DNA scaffold of
the extracellular traps,121 reportedly leading to the loss of its anti-
bacterial capacity.122,123 Stephan et al. reported the internalization
of LL-37:DNA complexes derived from NETs by macrophages
enabling antimicrobial activity of LL-37 against intracellular
pathogens.124
Lactoferrin, also known as lactotransferrin, is a basic iron-
binding glycoprotein of the secondary granules in neutro-
phils.125,126 Leukocytes, macrophages, platelets and bacteria, as
well as the gastrointestinal tract exhibit lactoferrin receptors.125
Lactoferrin is found to be associated to NETs.79 Lactoferrin exerts
a bacteriostatic effect through iron sequestering inhibition of the
bacterial proliferation.127 Additionally, lactoferrin is reported to
hold a bactericidal effect and inhibits the proliferation of fungi and
viruses.125 The protein modifies outer membrane of Gram-negative
bacteria by binding and releasing LPS. This way, lactoferrin also
enhances the entry of lysozyme into Gram-negative bacteria.128 The
modulation of bacterial cell membrane can be blocked by the
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lactoferrin may interfere with cellular mechanisms including DNA
and RNA synthesis, protein synthesis, expression of lymphocyte
surface markers, immunoglobulin secretion and interleukin-2
expression.125 Lactoferrin serves also as ligand for TLR4 of rheu-
matoid arthritis synovial fibroblasts stimulating increased expres-
sions of inflammatory cytokines and chemokines.130 Furthermore,
lactoferrin has been reported to inhibit spontaneous apoptosis in
human neutrophils if the iron saturation status is low.126
Neutrophil gelatinase-associated lipocalin (NGAL, also known as
lipocalin-2) is a member of the lipocalin family that is characterized
by the ability of transporting small lipophilic substances, binding to
specific cell-surface receptors and forming complexes with soluble
macromolecules.131 NGAL was first identified to be covalently
associated with MMP-9.132 Furthermore, NGAL-MMP-9 complex
can be observed in a ternary complex with tissue inhibitor of
metalloproteinase-1 (TIMP-1) that results in a 10-fold lower ac-
tivity of MMP-9.133 NGAL is able to bind to fMLP,134 PAF135 and
leukotriene B4.135 NGAL may also serve as a cofactor of microbial
killing by other proteins through the binding to microbicidal,
lipophilic ligands or modulating inflammatory responses induced
by neutrophils.136 Furthermore, NGAL has been found to bind to
bacterial catecholate-type ferric siderophores preventing growth
and spread of Myobacterium tuberculosis137 and E. coli.138 NGAL has
also been identified in NETs and to be involved in their bactericidal
effect in vitro.139
Lysozyme is a conserved hydrolytic antimicrobial protein that is
well known for its importance to host defense. Lysozyme is
expressed in phagocytes, hepatocytes, and epithelial cells of
mucosal surfaces as well as in body fluids such as blood, tears,
urine, saliva and milk.140 Almost 100 years ago, Fleming et al.
observed the bactericidal effect mediated by lysozyme.141 Lyso-
zyme provokes bacterial cell lysis through targeted hydrolysis of
the bacterial cell wall.141 Lysozyme is identified as a NET-associated
protein using a proteomic approach.79 Lysozyme is supposed to
contribute to the antimicrobial activity of NETs due to its action on
the bacterial wall.142
Matrix metalloproteases (MMPs) are characterized by their
dependence on intrinsic Zn2þ ions and extrinsic Ca2þ. Their many
function consist of degradation of all constitutes of the extracel-
lular matrix.68 Several MMPs are involved in the cleavage and
inactivation of a1-antitrypsin, an inhibitor of neutrophil elastase,
cathepsin G and proteinase 3.143 Likewise, serine proteases are
able to inactivate protease inhibitor like TIMP-1144 and cystatin
C145 that serve as inhibitors of MMPs. Metalloproteinase-8 (MMP-
8; also known as neutrophil collagenase or collagenase 2) is a
potent collagenase highly expressed by neutrophils146 as well as
rheumatoid synovial fibroblasts,147 endothelial cells,147 activated
macrophages,148 smooth muscle cells,149 bronchial epithelial
cells,148 mast cells150 and chondrocytes.151 MMP-8 are secreted in
tuberculosis-associated inflammation driving the tissue destruc-
tion through degradation of the collagen.152 MMP-8 mediates
responsiveness of neutrophils to LPS through chemokine modifi-
cation.153 Cleavage of collagen by MMP-8 facilitates neutrophil
migration to sites of inflammation and injury behind collagen-rich
barriers.146
Gelatinase granule proteins
Metalloproteinase-9 (MMP-9; also known as gelatinase B) is a
member of the MMP family and is secreted by endothelial cells,154
monocytes/macrophages,155 mast cells,156 eosinophils157 and neu-
trophils.158 MMP-9 degrades collagen, elastin and gelatin of the
extracellular matrix upon exocytosis.159 In allergic asthmatic pa-
tients MMP-9 is released by neutrophils after exposure toallergens.160 MMP-9 cleaves and inactivate SLPI at sites of inflam-
mation preventing its binding to LPS and inhibition of neutrophil
elastase activity.161 Several MMPs includingMMP-9 process human
IL-1b and TNF precursor into its biologically active form regulating
their appearance at inflammatory sites.162,163
Leukolysin, also known as membrane-type 6 metalloproteinase
(MT6-MMP, MMP25), is a GPI-anchored proteinase of the MMP
family.164 Leukolysin is expressed in leukocytes,165 in SW480 colon
carcinoma cells and several brain tumors including anaplastic as-
trocytomas and glioblastomas.166 Leukolysin is the most efficient
proteinase in the inactivation of a1-PI. a1-PI is found in high con-
centrations in interstital spaces and circulating plasma to protect
tissue from neutrophil serine proteases. Action of leukolysin
against a1-PI releases neutrophil elastase, proteinase 3 and
cathepsin G from its inhibitor leading ultimately to tissue
damage.167
Conclusions
Granule proteins are secreted from eosinophils and neutrophils
into the extracellular space upon activation and consist of a variety
of important mediators that are crucial for the function of gran-
ulocytes within the innate immunity. The released granule proteins
display a great variety of weapons and diverse antimicrobial
mechanism that are directed against different kind of pathogens
(Table 1). On the other hand, excessive production of granule pro-
teins of eosinophils and neutrophils plays a significant role in the
pathogenesis of diverse human diseases. These findings arise the
possibility to use granule proteins as diagnostic marker and drug
targets for the development of new therapeutics against infectious
and chronic inflammatory diseases. The understanding of the
functional consequences of the molecular interactions between
DNA and granule proteins within NETs and EETs requires additional
experimentation.
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